HYPERLIQUID STRATEGIES INC (PURR)

NASDAQFinancialsFinancial - Capital MarketsSnapshot 2026-10-23

$8.78+1.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge HYPERLIQUID STRATEGIES INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	13.03M
EPS	—	0.11
Annual ending 2027-06-30
Revenue	—	55.29M
EPS	—	0.245
Annual ending 2028-06-30
Revenue	—	72.64M
EPS	—	0.603

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Share buyback program execution	The company has a $30 million share buyback program supporting shareholder value.	Intact	Buyback program is cancelled or materially reduced	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
EPS improves toward breakeven	A primary condition in HYPERLIQUID STRATEGIES INC's published investment case. The stated target is EPS >= -0.50 next quarter.	Recovered	EPS remains below -0.90 next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue holds near $5.6 million	Revenue is expected near $5.6 million next quarter despite losses.	Intact	Revenue falls below $5.5 million next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-06-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	3	0	0
2026-06-01	3	0	0
2026-07-01	3	0	0
2026-08-01	3	0	0
2026-09-01	4	0	0
2026-10-01	4	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Share buyback program executionDirect metric needs a verified mapping
EPS improves toward breakevenDirect metric needs a verified mapping
Revenue holds near $5.6 millionDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-45.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

HYPERLIQUID STRATEGIES INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, crypto-linked financial business with a transition away from legacy bio-tech operations. Management has made progress on stated priorities, but the thesis state remains insufficient because there is not enough recent financial-performance history to assess it.

What's priced into HYPERLIQUID STRATEGIES INC

The valuation label recently changed from fair to inexpensive, but the evidence does not show what expectations the market already assumes. Fragility is rated low, though overall confidence in the assessment is low.

What the fundamentals likely do

Near term, erratic earnings surprises and the latest quarter’s miss make the next report an important check on execution. Over the multi-year view, management has expanded HYPE holdings and reported staking revenue, while completing most of the legacy bio-tech exit; progress on treasury growth and fee generation remains mixed.

What HYPERLIQUID STRATEGIES INC hinges on

The thesis depends on whether HYPE holdings can support more staking revenue and ecosystem fees, and whether management continues the stated capital-deployment plan. Near term, rate changes and results from financial-sector bellwethers could shape the sector backdrop; evidence here points to both favorable and unfavorable scenarios.

Bottom line

PURR has made tangible progress on its transition, but the latest earnings miss, mixed progress on key priorities, and low confidence leave the 1-to-3-year thesis unresolved. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.